(MedPage Today) — SAN FRANCISCO — Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral therapy (ART) avoided rebound for 5 months, a randomized trial showed.
At 20 weeks from analytical…
Source link : https://www.medpagetoday.com/meetingcoverage/croi/114589
Author :
Publish date : 2025-03-11 15:02:00
Copyright for syndicated content belongs to the linked Source.
